Evidence map›Paper›PMID 25709266›Full record

ReviewOman journal of ophthalmology

Gene therapy in keratoconus.

Mahgol Farjadnia, Mohammad Naderan, Mehrdad Mohammadpour

Open access · diamondAbstract readReview
In one paragraph

Review in Oman journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Update on the Physiopathology of Keratoconus.Medical sciences (Basel, Switzerland) · 2026
    Review
  2. Review
  3. New treatments for keratoconus.International ophthalmology · 2020
    Article
  4. Updates on Managements for Keratoconus.Journal of current ophthalmology · 2018
    Review
  5. Review
  6. Contact Lenses for Keratoconus- Current Practice.The open ophthalmology journal · 2017
    Article
  7. Genetics in Keratoconus - What is New?The open ophthalmology journal · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Mahgol FarjadniaEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad NaderanEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Mehrdad MohammadpourEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Tehran University of Medical Sciences · IRFarabi Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Keratoconus (KC) is the most common ectasia of the cornea and is a common reason for corneal transplant. Therapeutic strategies that can arrest the progression of this disease and modify the underlying pathogenesis are getting more and more popularity among scientists. Cumulating data represent strong evidence of a genetic role in the pathogenesis of KC. Different loci have been identified, and certain mutations have also been mapped for this disease. Moreover, Biophysical properties of the cornea create an appropriate candidate of this tissue for gene therapy. Immune privilege, transparency and ex vivo stability are among these properties. Recent advantage in vectors, besides the ability to modulate the corneal milieu for accepting the target gene for a longer period and fruitful translation, make a big hope for stupendous results reasonable.

Indexed as

Corneagene therapygeneticskeratoconus

Identifiers

PMID25709266
PMCPMC4333540
OpenAlexW2055268773

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.